[sentient Pharmaceutical Industry: the first participant enrolled in Phase b Clinical trial of a Class of innovative Drug ZSP1601 tablet Ⅱ] the first participant was enrolled in the phase b clinical trial of ZSP1601 tablet Ⅱ, an innovative drug for the treatment of non-alcoholic steatohepatitis (NASH) carried out by holding subsidiary Zhongsheng Ruichuang.